H.B. Fuller delivered the kind of margin quarter investors have waited for, but it came at what management describes as the peak of its price-versus-raw-materials advantage. Adjusted EPS of $1.52 beat the $1.45 consensus and the matching Earnings Whisper number by 4.8% and rose 20.6% from a year ago. Revenue of $938.18 million grew 5.2% but slipped 0.2% below consensus. That split is the central tension: earnings are growing much faster than the business, and nearly all of the top-line growth came from pricing rather than demand.
The composition of revenue deserves scrutiny. Pricing added 7.4% while volume fell 3.0%, producing 4.4% organic growth. That is a sharp acceleration from 2.6% in the second quarter and a 6.6% decline in the first, but the improvement reflects price increases, not a recovery in orders. The margin gains were real and broad-based. Adjusted gross margin rose 120 basis points to 33.5%, and adjusted EBITDA increased 9% to $187 million. The adjusted EBITDA margin reached a record 19.9%, just short of the company's greater-than-20% target, and all three business units expanded margins. Hygiene, Health and Consumable Adhesives improved to 17.6%, and Engineering Adhesives reached 23.8%. Adjusted SG&A still rose 8%, faster than revenue, and a lower adjusted tax rate of 25.0%, versus 25.7% a year ago, gave EPS a small lift. On a GAAP basis, diluted EPS was $1.44, versus $1.22 a year ago. The GAAP figure was supported by a $19.7 million unrealized gain on a currency forward tied to the AMS acquisition, which partly offset transaction costs and $7.8 million of debt extinguishment and bridge financing expenses.
The call offered a credible margin story but no demand story. Pricing exited the quarter at 7.6%, and further increases are still being implemented into the first half of 2027. Volumes did beat the guided mid-single-digit decline. Underneath, however, conditions softened in several areas. Chip shortages hurt electronics demand in Asia Pacific, reversing first-half strength. HHC volumes are down roughly 9% over two years as GLP-1 drugs and weak household formation weigh on the business. Packaging and construction remain sluggish. Most importantly, management said the price/raw spread peaked in the third quarter and will narrow in the fourth quarter and 2027 as delayed raw-material costs work through. The very lever that produced this beat is set to weaken.
Guidance moved modestly. The adjusted EPS range was tightened to $4.70-$4.85 from $4.60-$4.90, nudging the midpoint up slightly. The adjusted EBITDA range narrowed to $655-$670 million from $650-$675 million, leaving the midpoint essentially unchanged. The operating cash flow outlook of $300-$325 million was reaffirmed. With $486 million of adjusted EBITDA through nine months, the range implies fourth-quarter EBITDA of roughly $169-$184 million, compared with $170 million a year ago. That is consistent with a narrowing spread, and the outlook was a raise in form but remains in line with Street estimates.
The catalysts and risks are increasingly about the balance sheet and the portfolio. The Quantum Leap program should cut the plant count from 82 to about 62 by the end of 2026. Management quantified $20-$25 million of incremental savings for 2027, and expected real estate proceeds of about $33 million should more than offset roughly $50 million of one-time costs. Leverage improved to 3.0x from 3.3x a year ago. The AMS acquisition, however, is expected to close by year-end, lifting leverage to about 4x, with takeout financing at roughly 6.5%-7% fixed rates. Net working capital rose to 18.5% of annualized revenue from 16.4% last quarter, driven by strategic inventory building tied to the Middle East disruption. Shareholder pushback over AMS and the rejected unsolicited offer for Building Adhesive Solutions has shifted the conversation toward deleveraging, and management now openly acknowledges it could pursue divestitures.
The market has not rewarded the margin progress. Shares have fallen 18.3% since opening at $61.42 after the June report and now trade at $50.21, about 15.9% below the 200-day moving average. Earnings Whispers price and AVWAP trend readings are both negative. Investor sentiment swung decisively, from a positive 0.28 before the last report to a negative 0.25. That shift suggests the deal, leverage and governance overhang has outweighed the improving earnings trend.
The bottom line is that H.B. Fuller executed well on price and cost, delivering accelerating earnings growth and a record margin. The quarter likely represents peak spread, however, with volumes still shrinking and a more leveraged balance sheet ahead once AMS closes. Bears have legitimate ammunition on demand and debt. A re-rating likely depends on whether restructuring savings and possible divestitures can offset a narrowing spread in 2027.